Delivery Order SPE2DB24D3013-SPE2DB25FFLCX
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,381.02 to AmerisourceBergen Drug Corp for the supply of Opzelura 1.5% Cream in a 60-gram quantity. This competitively awarded, firm fixed-price delivery order was issued on October 22, 2025, with an ultimate completion date of October 23, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,406.37 to AmerisourceBergen Drug Corp for 60 grams of Opzelura 1.5% cream, a topical pharmaceutical product. This non-set-aside, firm fixed price delivery order was awarded on November 5, 2025, with an ultimate completion date of November 6, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary operations. This delivery order represents a...
- The Defense Logistics Agency awarded a $7,999.10 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60 grams of Opzelura 1.5% cream, with an ultimate completion date of November 17, 2025. This non-competitive, non-set-aside award represents a child delivery order under AmerisourceBergen's substantial indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $8.3K delivery order to AmerisourceBergen Drug Corp for 60 grams of Opzelura 1.5% cream on August 4, 2025, with completion targeted for August 5, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare...
- The Defense Logistics Agency awarded a delivery order valued at $7,101.39 to AmerisourceBergen Drug Corp for the supply of Opzelura 1.5% cream in 60-gram quantities. This competitively awarded, firm fixed-price delivery order was issued on October 24, 2025, with an ultimate completion date of October 27, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Opzelura 1.5% Cream in a 60-gram format, with a ceiling value of $2,046.89. This competitively awarded, firm fixed-price contract is classified as a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The delivery order carries...
- The Defense Logistics Agency awarded a delivery order valued at $1,807.26 to AmerisourceBergen Drug Corp for the supply of Opzelura 1.5% Cream in 60-gram units. This firm fixed-price contract, issued on October 31, 2025, with completion by November 3, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The award was made through open...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Opzelura 1.5% Cream in a 60-gram quantity, valued at $5,766.81. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitive award. The order is scheduled for completion by August 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child order under a larger contract...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on April 21, 2025, for the supply of Opzelura 1.5% cream in 60-gram quantities, with a contract ceiling value of $1,310.45. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded procurement. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of April 22, 2025....
- The Defense Logistics Agency awarded a delivery order valued at $3,358.40 to AmerisourceBergen Drug Corp for Opzelura 1.5% Cream (60 grams) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order is non-competitive and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999. The product will be performed at AmerisourceBergen's...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFLCXDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,031.11 to AmerisourceBergen Drug Corp for 60 grams of Opzelura 1.5% cream on April 22, 2025, with completion scheduled for April 23, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a pharmaceutical supply transaction under DLA's medical procurement operations, which support the Defense Health Agency and other federal healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen Drug Corp supplies a broad portfolio of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains to support military healthcare programs worldwide. The company's extensive contract history with DLA demonstrates its capability to fulfill federal pharmaceutical procurement requirements through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.0k | 4/22/25 |